Studies related to Bilirubin and Lactobacillus reuteri

Evaluation Of Clinical Safety And Tolerance Of A Lactobacillus Reuteri NCIMB 30242 Supplement Capsule: A Randomized Control Trial

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 124
Gender Both Genders
Age Range 30-44, 45-64
Body Types Overweight
Notes for this study:
Supplementation of _l. reuteri_ NCIMB 30242 at 2.9x10^9^ CFU twice daily in otherwise healthy hypercholesteromic adults for nine weeks did not appear to confer any significant toxic effects relative to placebo.

LDL cholesterol appeared to be reduced 11.7% with supplementation, but most other parameters were unchanged.
Funding issues for this study:
Funding provided by Micropharma, producer of Cardioviva

Safety And Tolerance Of Lactobacillus Reuteri Supplementation To A Population Infected With The Human Immunodeficiency Virus

Effect None
Trial Design Double blind
Trial Length 2-4 Weeks
Number of Subjects 39
Gender Both Genders
Age Range 18-29, 30-44, 45-64
Body Types Average
Notes for this study:
Supplementation of _l. reuteri_ at 10^10^ CFU in two divided doses a day for three weeks in persons with HIV failed to significantly influence any observed biochemical parameter to a level which was deemed practically relevant, with most parameters also failing to be significantly influenced.

Cholesterol-lowering Efficacy Of A Microencapsulated Bile Salt Hydrolase-active Lactobacillus Reuteri NCIMB 30242 Yoghurt Formulation In Hypercholesterolaemic Adults

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 114
Gender Both Genders
Age Range 30-44, 45-64
Body Types Overweight
Notes for this study:
_L. reuteri_ NCIMB at 5x10^9^ CFU daily for six weeks in persons with high cholesterol was able to moderately reduce both LDL cholesterol (8.92%) and total cholesterol (4.81%) with no influence on fecal bile acids nor other parameters of cardiovascular health.

Safety testing found supplementation to be well tolerated.
Funding issues for this study:
Some authors reported a potential conflict of interest as they are involved with the company which produces this strain (Micropharma limited)